Health UBRELVY® (ubrogepant) Recommended for Reimbursement by Canada’s Drug Agency (CDA-AMC) for Acute Migraine Treatment August 4, 2026
Health Nurix Therapeutics Announces First Patient Enrolled in Registrational Phase 3 DAYBreak CLL-306 Trial of Bexobrutideg in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma August 4, 2026
Health BrightSpring Health Services, Inc. Reports Second Quarter 2026 Financial Results and Increases Full Year 2026 Guidance July 31, 2026
Health Cytokinetics Announces MHRA Marketing Authorisation for MYQORZO®▼ (aficamten) and Positive Guidance from NICE for Symptomatic Obstructive Hypertrophic Cardiomyopathy in England and Wales July 30, 2026
Health Daxor Broadens Outpatient Footprint with Initiation of ezBVA Lab Diagnostic Services in Kansas July 30, 2026
Health MannKind Reports Positive Phase 1b INFLO-1 Results, Demonstrating Safety and Tolerability of Nintedanib DPI and Clinical Validation of Its DPI Technology in IPF July 29, 2026